Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Prelude Therapeutics (PRLD) Depreciation & Amortization (CF) (2024 - 2025)

Prelude Therapeutics' Depreciation & Amortization (CF) history spans 2 years, with the latest figure at $418000.0 for Q4 2025.

  • For Q4 2025, Depreciation & Amortization (CF) fell 14.52% year-over-year to $418000.0; the TTM value through Dec 2025 reached $1.7 million, down 3.44%, while the annual FY2025 figure was $1.7 million, 3.44% down from the prior year.
  • Depreciation & Amortization (CF) for Q4 2025 was $418000.0 at Prelude Therapeutics, down from $425000.0 in the prior quarter.
  • Across five years, Depreciation & Amortization (CF) topped out at $489000.0 in Q4 2024 and bottomed at $405000.0 in Q3 2024.